---
title: Electroacupuncture on Post-stroke Urinary Retention
nct_id: NCT02472288
overall_status: TERMINATED
phase: NA
sponsor: Kyunghee University
study_type: INTERVENTIONAL
primary_condition: Urinary Retention
countries: South Korea
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02472288.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02472288"
ct_last_update_post_date: 2016-08-31
last_seen_at: "2026-05-12T07:01:30.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Electroacupuncture on Post-stroke Urinary Retention

**Official Title:** Multicenter, Randomised Controlled Trial of Electroacupuncture Versus Sham Electroacupuncture for Urinary Retention of Poststroke Patients: a Study Protocol

**NCT ID:** [NCT02472288](https://clinicaltrials.gov/study/NCT02472288)

## Key Facts

- **Status:** TERMINATED
- **Why Stopped:** Difficulty in enrolling participants
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 25
- **Lead Sponsor:** Kyunghee University
- **Collaborators:** Daejeon University, DongGuk University
- **Conditions:** Urinary Retention, Stroke, Complication
- **Start Date:** 2015-04
- **Completion Date:** 2016-04
- **CT.gov Last Update:** 2016-08-31

## Brief Summary

This study aimed to evaluate the effectiveness of adjuvant electroacupuncture therapy for the post-stroke patients with urinary retention under conventional treatments, compared with sham electroacupuncture.

## Eligibility

- **Minimum age:** 19 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* male or female aged over 19
* Patients diagnosed with stroke (cerebral hemorrhage or infarction) based on the CT or MRI examination
* Those whose onset is within 2 years
* Those who have urinary retention after stroke onset (every PVR result is equal or more than 100ml on the 2 consecutive tests)
* Those who signed on the informed consent form

Exclusion Criteria:

* Patients who have any bleeding disorders based on medical history hearing
* Patients who have ever had any medical procedures or surgeries for peripheral vascular diseases based on medical history hearing
* Patients who have any psychiatry disorders based on medical history hearing
* Patients who have any severe diseases in lower urinary tract symptom based on medical history hearing
* Patients who have any acute or chronic infectious diseases in lower urinary tract symptom based on medical history hearing
* Acute stage stroke patients (onset within 1 week) whose Glasgow Coma Scale ≤ 8
* Patients who have fear about acupuncture
* Patients who have changed medications for urinary retention or relevant symptoms, such as urinary incontinence drugs or diuretics, within 3 days
* Female who diagnosed with pregnancy by urinalysis
* Those who primary or sub investigators judge not to be suitable for the study
```

## Arms

- **Electroacupuncture (EA) group** (EXPERIMENTAL) — 1. Electroacupuncture therapy (10 sessions in total, 5 per a week, 2 weeks)
2. BL31, BL32, BL33, and BL34 (total 8 acupoints, bilateral)
3. 20 minutes duration, middle frequency (30 Hz) of electrical stimulation
4. conventional treatments permitted
- **Sham group** (SHAM_COMPARATOR) — 1. Non-penetrating Park sham electroacupuncture treatment (10 sessions in total, 5 per a week, 2 weeks)
2. BL31, BL32, BL33, and BL34 (total 8 acupoints on the right and left sides)
3. 20 minutes duration, undelivered electrostimulation of middle frequency (30 Hz)
4. conventional treatments permitted

## Interventions

- **Electroacupuncture (EA)** (DEVICE) — The EA group receives 10 sessions of EA therapy (5 per a week, 2 weeks). After inserting needles by 5-10 mm (stainless steel, 0.25 mm in diameter and 4.0 mm in length, Dong Bang Acupuncture Inc., Korea) using the Park sham guide tube on the 8 points (BL31, BL32, BL33, and BL34, bilateral sides), de qi response is elicited. The electrical stimulation is then presented for 20 minutes by middle frequency (30 Hz) (STN-111, Stratek, Korea). Conventional treatments (western/traditional herbal medications, rehabilitation, or acupuncture without electro-stimulation for stroke, and western/traditional herbal medications or acupuncture without electro-stimulation for urinary retention) are allowed during the intervention period. The practitioner should have over 1-year clinical experiences.
- **Sham electroacupuncture** (DEVICE) — The patients in sham group receive totally 10 sessions of the sham EA (5 sessions per a week, for 2 weeks). Non-penetrating needles of Park sham device are implemented on the bilateral points of BL31, BL32, BL33, and BL34 (total 8 acupoints). Then, the electro-stimulation is presented for 20 minutes by middle frequency (30 Hz) (STN-111, Stratek, Korea), even though the electrical stimulation is not delivered through the skin. Conventional treatments for stroke and urinary retention along with EAT are not eliminated. It is also necessary for the practitioner with more than 1-year experiences on the clinical field.

## Primary Outcomes

- **Change of daily PVR (Postvoid Residual) urine ratios between the baseline and the endpoint** _(time frame: Day 0 (baseline), Day 14(endpoint))_ — * daily PVR ratio = daily PVR urine volume / (daily PVR urine volume + self voiding volume)
* Baseline measurement: daily PVR ratio for 24 hours on the day before the first intervention day Endpoint measurement: daily PVR ratio for 24 hours within 3 days after the last intervention day
* If more than 7 sessions of EA or sham EA are completed and urinary tract is not infected at the end, then the urine volume is measured on the next day of the last intervention.
* If more than 7 sessions of EA or sham EA are completed and urinary tract is infected at the end, then the urine volume is measured on the 3rd day of the last intervention after anti-infection treatment is carried out for 48 hours.

## Secondary Outcomes

- **Urinary tract infection (UTI)** _(time frame: Day 14(endpoint))_
- **Korean version of Qualiveen Questionnaire (K-QQ)** _(time frame: Day 0 (baseline), Day 14(endpoint))_
- **Korean version of International Prostate Symptom Scale (K-IPSS)** _(time frame: Day 0 (baseline), Day 14(endpoint))_
- **Blinding Index (BI)** _(time frame: Day 14(endpoint))_
- **Frequencies of urination and urinary incontinence** _(time frame: Day 0 (baseline), Day 14(endpoint))_
- **Adverse events** _(time frame: Every treatment visit (5 times during Day 1~Day 7 & 5 times during Day 8~Day 14))_

## Locations (3)

- Cheonan Korean Medicine Hospital of the Daejeon University, Cheonan, Chungcheongnam-do, South Korea
- Dongguk University Ilsan Oriental Hospital, Goyang-si, Gyeonggi-do, South Korea
- Kyung Hee University Korean Medicine Hospital, Seoul, South Korea

## Recent Field Changes (last 30 days)

- `locations.cheonan korean medicine hospital of the daejeon university|cheonan|chungcheongnam-do|south korea` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.dongguk university ilsan oriental hospital|goyang-si|gyeonggi-do|south korea` — added _(2026-05-12)_
- `locations.kyung hee university korean medicine hospital|seoul||south korea` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02472288.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02472288*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*